What is it about?
From 2000 onwards, patent filings and grants for biocompatible polymers are expanding. Currently definition of biocompatibility is quite ambiguous with respect to the use of FDA approved polymeric materials. This article analysed patent portfolios for the trend patterns of prolific biocompatible polymers for capitalization and commercialization in the forthcoming years.
Featured Image
Why is it important?
Pair Bulk Data (PBD) portal was used to mine patent portfolios. In this patent preliminary analysis report, patents from 2000 to 2015 were evaluated using 317(c) filings, grants and classifications data for poly(vinyl alcohol) (PVA), poly(glycolic acid) (PGA), poly(hydroxyalkanoates) (PHAs) and poly(lactic acid) (PLA).
Perspectives
This patent portfolio preliminary analysis embarks into patent analysis for New Product Development (NPD) for corporate R&D investment managerial decisions and on government advocacy for federal funding which is decisive for developmental advances. An in-depth patent portfolio investigation with return of investment (RoI) is in the pipeline.
Balu Ranganathan
Palms Connect LLC
Read the Original
This page is a summary of: Biocompatible Synthetic and Semi-synthetic Polymers - A Patent Analysis, Pharmaceutical Nanotechnology, April 2018, Bentham Science Publishers,
DOI: 10.2174/2211738505666171023152549.
You can read the full text:
Contributors
The following have contributed to this page
